FRM
MRTX

Fox Run Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Fox Run Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,840
Closed -$608K – 1058
2023
Q2 		$608K Buy
16,840
+5,541
+49% +$228K 0.17% 229
2023
Q1 		$420K Buy
+11,299
New +$508K 0.14% 278
2022
Q4 		– Sell
-6,569
Closed -$459K – 950
2022
Q3 		$459K Buy
6,569
+2,937
+81% +$217K 0.18% 201
2022
Q2 		$244K Buy
3,632
+182
+5% +$11.6K 0.12% 369
2022
Q1 		$284K Buy
+3,450
New +$353K 0.16% 295
2018
Q2 		– Sell
-9,744
Closed -$299K – 963
2018
Q1 		$299K Buy
+9,744
New +$270K 0.07% 493

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fox Run Management's MRTX Position: Q3 2023 in Review

Fox Run Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 16,840 shares — an estimated $608K sold.

Fox Run Management first reported a position in MRTX in Q1 2018 and held it in 6 quarters. The position peaked at $608K in Q2 2023. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Fox Run Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Fox Run Management sold 16,840 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $608K.
  • Fox Run Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 6 quarters.
  • Fox Run Management's Mirati Therapeutics, Inc. Common Stock position peaked at $608K in Q2 2023.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Fox Run Management's 13F filing for Q3 2023, filed 7 Nov 2023.